产业观察 [table_Header]2025.06.10 | | 【数字经济周报】博通推出 Tomahawk 6：世界上第 | 产业研究中心 | | | --- | --- | --- | --- | | 一台 | 102.4 Tbps 交换机 | [Table_Authors] | 朱峰(分析师) | | | 摘要：数字经济动态事件速览 第 17 期（2025.05.31-2025.06.06） | | 021-38676666 | | | [Table_Summary] 半导体板块动态： | 登记编号 | S0880522030002 | | | 1） 寒武纪：49.8 亿元定增申请获上交所受理 | | | | | 博通推出 交换机芯片 2） Tomahawk 6：全球首款 102.4 Tbps | | | | | 3） GlobalFoundries 宣布在美国投资 160 亿美元 | | 鲍雁辛(分析师) | | | 汽车电子板块动态 | | 021-38676666 | | | 1）小鹏联手华为推出 AR-HUD | 登记编号 | S0880513070005 | | | 2）蔚来公司 5 月交付 ...

Core Viewpoint - The article discusses the current state of the stock market, highlighting mixed performance across various indices and sectors, with a focus on the strength of certain stocks and sectors while others are experiencing declines [1][4]. Market Performance - As of June 10, the Shanghai Composite Index rose by 0.11% to 3403.52, while the Shenzhen Component Index fell by 0.23% to 10226.55, and the ChiNext Index decreased by 0.36% to 2053.94 [2][1]. - Overall, the market saw more declines than gains, with nearly 3400 stocks experiencing a drop [2]. Sector Performance - The pharmaceutical sector, particularly CRO (Contract Research Organization) stocks, showed strong performance, along with new consumption, solid-state batteries, and cross-border e-commerce concepts [4]. - Conversely, sectors such as computing, aerospace, AI applications, semiconductors, and new energy vehicles faced declines [4]. Capital Flow - Major inflows were observed in banking, pharmaceutical biology, electric equipment, public utilities, basic chemicals, non-ferrous metals, and light industry manufacturing sectors [5]. - Specific stocks like Industrial and Commercial Bank of China, Leshan Electric Power, and Bank of China saw net inflows of 742 million, 658 million, and 484 million respectively [6]. - On the other hand, stocks such as Huibo Yuntong, Inspur Information, and Tuo Wei Information faced significant net outflows of 323 million, 318 million, and 309 million respectively [7]. Asia-Pacific Market Overview - Major Asia-Pacific indices showed positive performance, with the Nikkei 225 rising by 1.01% to 38473.97, and the Korean Composite Index increasing by 0.75% to 2877.23 [9][10]. - The Australian S&P 200 Index also saw a rise of 0.79% to 8582.7 [10]. Market Sentiment and Strategy - Market volume remains insufficient, with a current level around 1.2 trillion, leading to a cautious outlook without significant policy breakthroughs [11]. - The strategy of focusing on individual stocks rather than indices is suggested, especially in sectors like smart manufacturing, military industry, and pharmaceuticals, which have shown recent performance but may not fully reflect long-term expectations [12].

2025.06. 09 贵金属板块早盘走低，午后逐步回升，赤峰黄金、四川黄金、山东黄金等多股跌幅收窄至逾1%。 本文字数：616，阅读时长大约2分钟 作者 | 一财资讯 6月9日，三大股指集体收涨，上证指数涨0.43%，深成指涨0.65%，创业板指涨1.07%，市场逾4100股 上涨。 盘面上，医药股爆发，CRO、创新药方向领涨，大金融板块活跃；稀土永磁、军工、数字货币、固态电池 题材强势。 | 板块名称 | 涨幅量 | 主力净量 | 主力金额 | 板块名称 | 涨幅4 | 主力净量 | 主力金额 | | --- | --- | --- | --- | --- | --- | --- | --- | | CRO概念 | +4.73% | 1.59 | +8.09 7. | 公路铁路运输 | -0.59% | -0.03 | -50767 | | 減肥药 | +4.66% | 0.61 | +1.9747. | 我懂得 | -0.30% | -0.33 | -3.25 Z | | 足球概念 | +4.44% | 1.10 | +4.03 7. | 贵金属 | -0.24% | -2.22 | -4.82 7 | ...

6月9日，A股三大指数高开高走，创业板领涨。 IP经济概念持续走高 医药股爆发，CRO、创新药方向领涨；券商、军工涨幅靠前；稀土永磁、AI应用、足球产业、数字货币、固态电池题材活跃。 港股方面，恒生指数涨超1%，恒生科技指数涨近3%。中国稀土（000831）涨超40%，信达生物涨超8%，泡泡玛特盘中股价再创新高，一度涨逾3%。 港股汇彩控股暂停交易 港股汇彩控股今日午后放量闪崩，公司宣布临时停牌。截至停牌前，汇彩控股跌47.54%，报0.96港元，成交额2420.12万港元。 资料显示，汇彩控股是一家主要从事提供娱乐场管理服务业务的投资控股公司。公司通过两个业务分部进行运营。娱乐场服务分部从事向澳门娱乐场提供 管理服务业务。博彩系统分部从事开发、提供及销售电子博彩系统业务。该公司也通过其子公司从事市场开发、软件开发业务。 消息面上，近日媒体报道，澳门特区政府修改《2025年财政年度预算案》，建议将今年全年博彩毛收入估算从原来的2400亿澳门元下调至2280亿澳门元， 并以此作为修改后预算的主要财政收入基础。因全年博彩毛收入估算下调，澳门特区政府将本年度一般综合预算收入修改为1165亿澳门元，开支总额修改 为1 ...

创新药爆发 机构表示看好行业有望迎来系统性投资机会 金十数据6月9日讯，今天上午，A股概念板块涨幅榜前列被多个医药细分板块"霸屏"，CRO、化学制 药、创新药、医疗服务等板块大涨。由于市场担忧2025年美国临床肿瘤学会大会闭幕后，创新药板块缺 乏后续催化剂，上周后半周，创新药板块连续调整。爱建证券表示，本轮创新药行情反映了未来3—5年 维度，中国创新药出海的产业趋势。目前，中国医药产业在ADC、双抗、细胞治疗等领域处于全球创 新第一梯队，在研发和生产端的成本优势、技术平台优势明显。同时，在与全球MNC（跨国企业）不 断达成重磅BD（商务拓展）交易的推动下，中国创新药在全球市场的认可度和影响力快速提升，进一 步推动创新出海加速，形成"正反馈"的良性循环。平安医药精选基金经理周思聪表示， 2025年是中国 创新药行业的"三个元年"——收入放量元年、盈利跨越元年和估值抬升元年，行业有望迎来系统性投资 机会。 （中证金牛座） ...

2025.06. 09 本文字数：507，阅读时长大约2分钟 作者 | 一财资讯 6月9日午盘，上证指数涨0.23%，深成指涨0.62%，创业板指涨1.22%。创新药概念领涨，稀土永磁、 固态电池、数字货币板块走势强劲；黄金、白酒板块表现低迷。 | | | | | A股重要 行政 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | | 最新 | How | | 涨幅 | | 上证指数 | | | | 6393.26 | +7.04-11 | | +1 7 4 76 | | 深证成指 | | | | 02246965 | + 174 5 | | +0.62% | | 比亚 50 | | | | | 41.5.44 | | + 1.0 11.11% | | 创业板指 | | | | 2064.40 | +24.96 | | + 1/4/ | | 板块名称 | 行榜 1 | 主力浄量 | 主力金额 | 板块名称 | 涨幅 | 主力浄量 | 王力金额 | | 減肥药 | +4.79% | 0.55 | +4.67 7. | 贵金属 ...

Core Viewpoint - Despite external negative disturbances, internal support forces are strong, limiting the downward space of stock indices, with a high probability of short-term index fluctuations [5] Group 1: Market Trends - The solid-state battery sector is gaining strength, with companies like Yinglian Co. and Dexin Technology hitting the daily limit [2] - The CRO sector in pharmaceuticals is also performing well, with companies like Lianhua Technology reaching the daily limit [5] - The agricultural pesticide sector continues its strong performance, with Changqing Co. achieving consecutive gains [5] Group 2: Institutional Insights - CITIC Securities suggests avoiding macro disturbances and focusing on industrial trends, indicating a transitional phase before a potential bull market in the third to fourth quarter [3] - CITIC Jiantou emphasizes the importance of tracking capital flows and industry sentiment in June, a key period for dividend distribution, to identify high-dividend investment opportunities [4]

暗盘资金一眼洞悉庄家意图>> CRO概念板块走高，联化科技（002250）涨停，睿智医药（300149）涨超10%，美诺华（603538）、金 凯生科（301509）、圣诺生物、万邦医药（301520）、皓元医药等跟涨。 ...

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from July 3, 2023, to February 28, 2025, seeking damages for misleading statements regarding the company's business and financial prospects [1][5]. Company Overview - Fortrea Holdings, Inc. is a global contract research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [3]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [3]. - Fortrea claims to have the scale and expertise to deliver tailored solutions to its customers, with a portfolio of long-term projects that provide visibility into future revenues [3][4]. Financial Performance and Projections - In March 2024, Fortrea targeted an adjusted EBITDA margin of approximately 13% for 2025, which was later revised to a range of 11% to 12% in August 2024, still representing a projected increase of 30% to 40% in adjusted EBITDA dollars [5]. - Following the class action allegations, Fortrea's financial performance has been called into question, with claims that the company overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition services agreements (TSAs) [5][10]. Market Reactions and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in the company's business model amid pressures on biotechnology funding [6][7]. - Following a downgrade by Baird Equity Research on December 6, 2024, Fortrea's stock price fell significantly due to concerns about the company's communication and performance post-spin [8]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligning with prior expectations, leading to a substantial drop in stock price [9]. Credit Rating and Future Outlook - After the Class Period, Fitch Ratings downgraded Fortrea, projecting a 2025 EBITDA margin of 7.0% to 8.0%, a significant decline from earlier projections of 11% to 13% [10].

Financial Data and Key Metrics Changes - The company generated net sales of $116 million in Q1 2025, a decrease of 14% compared to $135 million in Q1 2024 [6][16] - Adjusted EBITDA for Q1 2025 was $3 million, down from $15.5 million in the same period last year [6][16] - Operating expenses decreased by $5 million year-over-year [5][10] - Gross profit margin declined to 26% in Q1 2025 from 31% in the previous year [18] Business Line Data and Key Metrics Changes - Metem sales increased by 14% year-over-year, while Diamond sales rose by 17% due to increased peanut acreage [8][9] - The absence of a previously canceled herbicide product negatively impacted sales [16] - The company faced challenges in the Mexican agave market and drought conditions in Australia, affecting overall performance [8][16] Market Data and Key Metrics Changes - Inventory levels at distributors are down nearly 23% compared to the previous year, indicating a prolonged destocking period [24] - Corn plantings are at historically high levels, which may positively impact demand for the company's products [24] - The company noted a competitive pricing environment, particularly in the fungicide and herbicide categories [56][58] Company Strategy and Development Direction - The company is focused on cost containment and improving net working capital, with a goal of achieving a 15% adjusted EBITDA margin over the long term [10][48] - A transformation plan is in place to streamline operations and improve financial results [26] - The company is exploring options for a longer-term capital structure to replace its current credit agreement [21] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about a recovery in demand as inventory levels are at historic lows [23][62] - The company has adjusted its full-year adjusted EBITDA target range to $40 million to $44 million, down from $45 million to $52 million [12] - Management highlighted the importance of executing the transformation plan to position the company for a cyclical upturn [22][26] Other Important Information - The company faced delays in filing its 10-K and 10-Q due to internal control matters and the need for a detailed review of major assets [13][15] - The company is working on a remediation plan to address identified material weaknesses in internal controls [15] Q&A Session Summary Question: Can you elaborate on the year-over-year top line performance? - Management noted that the removal of the Dactyl product significantly impacted top line sales, along with challenges in the agave market and drought in Australia [31][32] Question: What are the expectations for cash taxes this year? - The company expects cash taxes to be in the range of $4 million to $5 million due to international obligations [43] Question: Can you provide details on pricing pressures and competitive environment? - Management indicated that competitive pricing was influenced by inventory levels and not necessarily by specific product competition, with expectations for improvement in the future [56][58]